Upstream Bio, Inc. (NASDAQ:UPB – Free Report) – William Blair issued their Q4 2024 earnings per share (EPS) estimates for shares of Upstream Bio in a report issued on Tuesday, November 5th. William Blair analyst M. Phipps expects that the company will post earnings of ($0.42) per share for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Upstream Bio’s FY2025 earnings at ($2.36) EPS, FY2026 earnings at ($2.64) EPS, FY2027 earnings at ($2.15) EPS and FY2028 earnings at ($2.26) EPS.
UPB has been the topic of a number of other research reports. Piper Sandler assumed coverage on Upstream Bio in a report on Tuesday. They issued an “overweight” rating and a $75.00 price objective on the stock. JPMorgan Chase & Co. initiated coverage on shares of Upstream Bio in a research report on Tuesday. They issued an “overweight” rating and a $38.00 target price for the company. Finally, TD Cowen started coverage on shares of Upstream Bio in a research report on Tuesday. They set a “buy” rating on the stock.
Upstream Bio Stock Up 1.7 %
Shares of NASDAQ:UPB opened at $27.02 on Thursday. Upstream Bio has a 1 year low of $20.74 and a 1 year high of $29.46.
Insider Buying and Selling at Upstream Bio
In other news, Director Erez Chimovits acquired 825,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was purchased at an average price of $17.00 per share, with a total value of $14,025,000.00. Following the completion of the acquisition, the director now owns 4,554,873 shares of the company’s stock, valued at $77,432,841. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Upstream Bio news, major shareholder Ai Upstream Llc bought 1,175,000 shares of Upstream Bio stock in a transaction on Tuesday, October 15th. The shares were bought at an average price of $17.00 per share, for a total transaction of $19,975,000.00. Following the completion of the transaction, the insider now directly owns 1,175,000 shares of the company’s stock, valued at $19,975,000. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Erez Chimovits purchased 825,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $14,025,000.00. Following the purchase, the director now owns 4,554,873 shares in the company, valued at approximately $77,432,841. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.
About Upstream Bio
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Further Reading
- Five stocks we like better than Upstream Bio
- Insider Buying Explained: What Investors Need to Know
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- Overbought Stocks Explained: Should You Trade Them?
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Following Congress Stock Trades
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.